In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.
ACVC Clinical Decision-Making Toolkit

One of the best tools to help practitioners make the best bedside clinical decisions when managing patients with acute cardiovascular disease.

See more
Be Guidelines Smart

A comprehensive guidelines implementation toolkit especially for Nurses & Allied Professionals. 

See more

Risk assessment

ESC CVD Calculation Risk App

ESC CVD Calculation Risk App

Your CVD risk calculators in one app

  • Assess individual cardiovascular risk for different patient populations
  • Includes up to 10-year risk and lifetime risk calculators

Risk prediction tools

The article "Risk prediction tools in cardiovascular disease prevention" provides a summary of the available risk prediction algorithms and offers guidance on how to use them.

How to use risk predictions tools in daily practice

Use risk prediction tools to identify and motivate high risk patients and to assist your clinical decisions-making process

The SMART Risk Score

Easy-to-use, online tool to estimate 10-year risk for recurrent vascular events in patients with manifest cardiovascular disease.

How to approach your patient

This part shows cognitive behavioural methods as the effective ways to help people to adopt a healthy lifestyle.

Individual risk assessment in secondary prevention for cardiovascular disease

Better individualised estimates of risk in patients with previous cardiovascular disease will enable more intensive treatment, motivation and follow-up in identified high-risk individuals.

The ESC Prevention of Cardiovascular Disease programme is supported by AMGEN, AstraZeneca, Ferrer for good, and Sanofi and Regeneron in the form of educational grants.